Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Oct;34(10):2009–2012. doi: 10.1128/aac.34.10.2009

Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase.

S Loya 1, R Tal 1, Y Kashman 1, A Hizi 1
PMCID: PMC171980  PMID: 1705412

Abstract

We studied the effect of the natural marine substance illimaquinone on the catalytic activities of reverse transcriptase from human immunodeficiency virus type 1. Illimaquinone inhibited the RNase H activity of the enzyme at concentrations of 5 to 10 microgram/ml, whereas RNA-dependent DNA polymerase and DNA-dependent DNA polymerase activities were considerably less susceptible to this inhibition. Two synthetic derivatives of illimaquinone, in which the 6'-hydroxyl group at the ortho position to one of carbonyl groups of the quinone ring was modified, proved ineffective in inhibiting the human immunodeficiency virus type 1 reverse transcriptase RNase H function, suggesting involvement of the 6'-hydroxyl group in blocking the enzymatic activity.

Full text

PDF
2009

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anand R., Moore J. L., Curran J. W., Srinivasan A. Interaction between rifabutin and human immunodeficiency virus type 1: inhibition of replication, cytopathic effect, and reverse transcriptase in vitro. Antimicrob Agents Chemother. 1988 May;32(5):684–688. doi: 10.1128/aac.32.5.684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Balzarini J., Mitsuya H., De Clercq E., Broder S. Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV). Int J Cancer. 1986 Mar 15;37(3):451–457. doi: 10.1002/ijc.2910370318. [DOI] [PubMed] [Google Scholar]
  3. Basu A., Nanduri V. B., Gerard G. F., Modak M. J. Substrate binding domain of murine leukemia virus reverse transcriptase. Identification of lysine 103 and lysine 421 as binding site residues. J Biol Chem. 1988 Feb 5;263(4):1648–1653. [PubMed] [Google Scholar]
  4. Basu A., Tirumalai R. S., Modak M. J. Substrate binding in human immunodeficiency virus reverse transcriptase. An analysis of pyridoxal 5'-phosphate sensitivity and identification of lysine 263 in the substrate-binding domain. J Biol Chem. 1989 May 25;264(15):8746–8752. [PubMed] [Google Scholar]
  5. Clark P. K., Ferris A. L., Miller D. A., Hizi A., Kim K. W., Deringer-Boyer S. M., Mellini M. L., Clark A. D., Jr, Arnold G. F., Lebherz W. B., 3rd HIV-1 reverse transcriptase purified from a recombinant strain of Escherichia coli. AIDS Res Hum Retroviruses. 1990 Jun;6(6):753–764. doi: 10.1089/aid.1990.6.753. [DOI] [PubMed] [Google Scholar]
  6. De Clercq E. Suramin in the treatment of AIDS: mechanism of action. Antiviral Res. 1987 Jan;7(1):1–10. doi: 10.1016/0166-3542(87)90034-9. [DOI] [PubMed] [Google Scholar]
  7. Hirsch M. S. AIDS commentary. Azidothymidine. J Infect Dis. 1988 Mar;157(3):427–431. doi: 10.1093/infdis/157.3.427. [DOI] [PubMed] [Google Scholar]
  8. Hizi A., Hughes S. H. Expression in Escherichia coli of a Moloney murine leukemia virus reverse transcriptase whose structure closely resembles the viral enzyme. Gene. 1988 Jun 30;66(2):319–323. doi: 10.1016/0378-1119(88)90369-1. [DOI] [PubMed] [Google Scholar]
  9. Hizi A., Hughes S. H., Shaharabany M. Mutational analysis of the ribonuclease H activity of human immunodeficiency virus 1 reverse transcriptase. Virology. 1990 Apr;175(2):575–580. doi: 10.1016/0042-6822(90)90444-v. [DOI] [PubMed] [Google Scholar]
  10. Hizi A., Joklik W. K. RNA-dependent DNA polymerase of avian sarcoma virus B77. I. Isolation and partial characterization of the alpha, beta2, and alphabeta forms of the enzyme. J Biol Chem. 1977 Apr 10;252(7):2281–2289. [PubMed] [Google Scholar]
  11. Hizi A., McGill C., Hughes S. H. Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1218–1222. doi: 10.1073/pnas.85.4.1218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jeffries D. J. The antiviral activity of dideoxycytidine. J Antimicrob Chemother. 1989 Jan;23 (Suppl A):29–34. doi: 10.1093/jac/23.suppl_a.29. [DOI] [PubMed] [Google Scholar]
  13. Krug M. S., Berger S. L. Ribonuclease H activities associated with viral reverse transcriptases are endonucleases. Proc Natl Acad Sci U S A. 1989 May;86(10):3539–3543. doi: 10.1073/pnas.86.10.3539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Larder B., Purifoy D., Powell K., Darby G. AIDS virus reverse transcriptase defined by high level expression in Escherichia coli. EMBO J. 1987 Oct;6(10):3133–3137. doi: 10.1002/j.1460-2075.1987.tb02623.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Leuthardt A., Le Grice S. F. Biosynthesis and analysis of a genetically engineered HIV-1 reverse transcriptase/endonuclease polyprotein in Escherichia coli. Gene. 1988 Aug 15;68(1):35–42. doi: 10.1016/0378-1119(88)90596-3. [DOI] [PubMed] [Google Scholar]
  16. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911–1915. doi: 10.1073/pnas.83.6.1911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mitsuya H., Broder S. Strategies for antiviral therapy in AIDS. 1987 Feb 26-Mar 4Nature. 325(6107):773–778. doi: 10.1038/325773a0. [DOI] [PubMed] [Google Scholar]
  18. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Perrino F. W., Loeb L. A. Differential extension of 3' mispairs is a major contribution to the high fidelity of calf thymus DNA polymerase-alpha. J Biol Chem. 1989 Feb 15;264(5):2898–2905. [PubMed] [Google Scholar]
  20. Prasad V. R., Goff S. P. Linker insertion mutagenesis of the human immunodeficiency virus reverse transcriptase expressed in bacteria: definition of the minimal polymerase domain. Proc Natl Acad Sci U S A. 1989 May;86(9):3104–3108. doi: 10.1073/pnas.86.9.3104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rozenbaum W., Dormont D., Spire B., Vilmer E., Gentilini M., Griscelli C., Montagnier L., Barre-Sinoussi F., Chermann J. C. Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome. Lancet. 1985 Feb 23;1(8426):450–451. doi: 10.1016/s0140-6736(85)91162-6. [DOI] [PubMed] [Google Scholar]
  22. Sarin P. S., Sun D., Thornton A., Müller W. E. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone. J Natl Cancer Inst. 1987 Apr;78(4):663–666. [PubMed] [Google Scholar]
  23. Sarin P. S., Taguchi Y., Sun D., Thornton A., Gallo R. C., Oberg B. Inhibition of HTLV-III/LAV replication by foscarnet. Biochem Pharmacol. 1985 Nov 15;34(22):4075–4079. doi: 10.1016/0006-2952(85)90392-2. [DOI] [PubMed] [Google Scholar]
  24. Schinazi R. F., Eriksson B. F., Hughes S. H. Comparison of inhibitory activities of various antiretroviral agents against particle-derived and recombinant human immunodeficiency virus type 1 reverse transcriptases. Antimicrob Agents Chemother. 1989 Jan;33(1):115–117. doi: 10.1128/aac.33.1.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Starnes M. C., Cheng Y. C. Human immunodeficiency virus reverse transcriptase-associated RNase H activity. J Biol Chem. 1989 Apr 25;264(12):7073–7077. [PubMed] [Google Scholar]
  26. Vrang L., Oberg B. PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase. Antimicrob Agents Chemother. 1986 May;29(5):867–872. doi: 10.1128/aac.29.5.867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Yarchoan R., Klecker R. W., Weinhold K. J., Markham P. D., Lyerly H. K., Durack D. T., Gelmann E., Lehrman S. N., Blum R. M., Barry D. W. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986 Mar 15;1(8481):575–580. doi: 10.1016/s0140-6736(86)92808-4. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES